Bavarian Nordic Receives Positive CHMP Opinion for Including Mpox Real-world Effectiveness Data in European Marketing Authorization for Smallpox and Mpox Vaccine
July 26, 2024 02:00 ET
|
Bavarian Nordic A/S
Real-world data demonstrating vaccine effectiveness against mpox of up to 90% after two MVA-BN doses and a significant reduction of the risk of mpox-related hospitalizations COPENHAGEN, Denmark,...
Bavarian Nordic modtager anbefaling fra det Europæiske Lægemiddelagentur om opdatering af markedsføringstilladelse for koppe- og mpox-vaccine til at inkludere data for brugen af vaccinen mod mpox fra den virkelige verden
July 26, 2024 02:00 ET
|
Bavarian Nordic A/S
Data fra brugen af vaccinen fra den virkelige verden viser effektivitet på op mod 90% mod mpox efter vaccination med to doser MVA-BN samt at vaccinen reducerer risikoen for indlæggelse markant efter...
Bavarian Nordic Receives EMA Filing Acceptance and Validation of the MAA for its Chikungunya Vaccine
July 18, 2024 03:15 ET
|
Bavarian Nordic A/S
EMA will now initiate its centralized review procedure under accelerated assessment for Bavarian Nordic’s chikungunya vaccine COPENHAGEN, Denmark, July 18, 2024 – Bavarian Nordic A/S (OMX: BAVA)...
Bavarian Nordic modtager accept fra de europæiske lægemiddelmyndigheder af registreringsansøgningen for chikungunyavaccine
July 18, 2024 03:15 ET
|
Bavarian Nordic A/S
EMA påbegynder nu den fremskyndede vurdering af Bavarian Nordics chikungunyavaccine under den centraliserede procedure KØBENHAVN, Danmark, 18. juli 2024 – Bavarian Nordic A/S (OMX: BAVA) meddelte i...
Bavarian Nordic Converts Existing Credit Facility into Sustainability-linked Loan
July 01, 2024 02:30 ET
|
Bavarian Nordic A/S
COPENHAGEN, Denmark, July 1, 2024 – Bavarian Nordic today announced the conversion of its existing undrawn DKK 1 billion syndicated revolving credit facility (RCF) into a sustainability-linked loan...
Bavarian Nordic konverterer eksisterende kreditfacilitet til bæredygtighedsrelateret lån
July 01, 2024 02:30 ET
|
Bavarian Nordic A/S
KØBENHAVN, Danmark, 1. juli 2024 – Bavarian Nordic meddelte i dag, at selskabets eksisterende uudnyttede syndikerede revolverende kreditfacilitet på DKK 1 mia. er blevet konverteret til et...
Bavarian Nordic Joins Global Efforts to Fight Mpox Outbreak in Africa
June 28, 2024 10:27 ET
|
Bavarian Nordic A/S
Bavarian Nordic is committed to support global efforts to address the mpox situation in Africa through a donation of 15,000 doses of mpox vaccineEmergency Use Authorization for the MVA-BN vaccine has...
Bavarian Nordic tilslutter sig globalt initiativ i kampen mod mpox i Afrika
June 28, 2024 10:27 ET
|
Bavarian Nordic A/S
Bavarian Nordic vil støtte globalt initiativ for at løse mpox-situationen i Afrika gennem tilsagn om donation af 15.000 doser mpox-vaccineDR Congo har udstedt nødbrugstilladelse for MVA-BN-vaccinen ...
Bavarian Nordic Submits Marketing Authorization Application for its Chikungunya Vaccine Candidate to EMA
June 26, 2024 04:25 ET
|
Bavarian Nordic A/S
Regulatory review of the single-dose CHIKV VLP vaccine candidate for immunization to prevent disease caused by chikungunya virus infection in individuals 12 years of age and older is now underway in...
Bavarian Nordic indsender registreringsansøgning for chikungunyavaccine til de europæiske sundhedsmyndigheder
June 26, 2024 04:25 ET
|
Bavarian Nordic A/S
Myndighedsbehandling af enkelt-dose CHIKV VLP-vaccinekandidat til forebyggende immunisering mod sygdom forårsaget af chikungunyavirus for personer i alderen 12 år og opefter pågår nu både i EU og USA ...